Skip to main content

Advertisement

SpringerLink
Log in

The concept and application of antisense oligonucleotides

  • Rapid Communications
  • Published:
Diseases of the Colon & Rectum

Abstract

Since the identification of the double-stranded DNA helix by Watson and Crick in 1953, the knowledge of nucleotide structure and function has been an important potential tool in the study and therapy of disease. There is recent clinical evidence that antisense oligonucleotides may be important therapeutic compounds in the clinical therapy of a range of diseases, including infection (viruses and bacteria), oncology, and inflammation. Our laboratory-based understanding of antisense oligonucleotide activity has provided a foundation for their use in several human diseases. Potentially relevant applications include inflammatory bowel disease therapy, psoriasis, transplantation, rheumatoid arthritis, cytomegalovirus retinitis, hepatitis C, and solid tumor therapy. Here we will outline these applications as well as our ongoing clinical trials for Crohn's disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Crooke ST. Antisense technology part A. In: Methods in enzymology 313. New York: Academic Press, 2000:3–45.

    Google Scholar 

  2. Bennett CF, Cowsert LM. Antisense oligonucleotides as a tool for gene functionalization and target validation. Biochim Biophys Acta 1999;1489:19–30.

    Google Scholar 

  3. Hodges D, Crooke ST. Inhibition of splicing of wild-type and mutated luciferase-adenovirus pre-mRNAs by antisense oligonucleotides. Mol Pharmacol 1995;48:905–18.

    Google Scholar 

  4. Karras JG, McKay RA, Lu T, Dean NM, Monia BP. Antisense inhibition of membrane-bound human interleukin-5 receptor-alpha chain does not affect soluble receptor expression and induces apoptosis in TF-1 cells. Antisense Nucleic Acid Drug Dev 2000;10:347–57.

    Google Scholar 

  5. Levin AA. A review of issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta 1999;1489:69–84.

    Google Scholar 

  6. Yacyshyn BR, Lazarovits A, Tsai V, Matejko K. Crohn's disease, ulcerative colitis and normal intestinal lymphocytes express integrins in a dissimilar pattern. Gastroenterology 1994;107:1364–71.

    Google Scholar 

  7. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L,et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 1998;114:1133–42.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Isis Pharmaceuticals, Carlsbad Research Center, Carlsbad, California

    Stanley T. Crooke M.D., Ph.D.

  2. Division of Gastroenterology, University of Alberta, 2E3.11 Walter Mackenzie Centre, T6G 2R7, Edmonton, AB, Canada

    Bruce R. Yacyshyn M.D. (F.R.C.P.C.)

Authors
  1. Bruce R. Yacyshyn M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stanley T. Crooke M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Yacyshyn, B.R., Crooke, S.T. The concept and application of antisense oligonucleotides. Dis Colon Rectum 44, 1241–1243 (2001). https://doi.org/10.1007/BF02234777

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02234777

Key words

Search

Navigation